Andrew Blauvelt - Concepedia

Author

Andrew Blauvelt

Also Known As

A Blauvelt, A. Blauvelt, ANDREW BLAUVELT, Andrew Blauvelt, Andrew Blauvelt,, Andrew Blauvelt, Blauvelt, Andrew, Blauvelt,Andrew, D Yan, Hany Elmaraghy

805

Publications

36.4K

Citations

H-Index

108

Concepts

All Affiliations

Oregon Medical Research Center Probity Medical Research Icahn School of Medicine at Mount Sinai Oregon Health & Science University National Cancer Institute

About

Andrew Blauvelt is an author at Oregon Medical Research Center specializing in medicine, dermatology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	78	12.3K
2	Arts	1	1	391
3	Engineering	1	1	10
4	Health Sciences	1	1	266
5	Humanities	1	1	391

Andrew Blauvelt

248

Publications

31.1K

Citations

H-Index

Page 1

	Year	Citations
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky, New England Journal of Medicine	2016	2K
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, The Lancet AllergyAtopic DermatitisAllergy MedicineModerate-to-severe Atopic DermatitisSkin Allergy	2017	1.2K
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, Journal of the American Academy of Dermatology	2017	838
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Kenneth B. Gordon, Andrew Blauvelt, Kim Papp, New England Journal of Medicine	2016	818
Human skin Langerhans cells are targets of dengue virus infection Shuenn-Jue L. Wu, Géraldine Grouard-Vogel, Wellington Sun, Nature Medicine Dengue Virus InfectionPathogenesisViral PathogenesisImmunologyHumoral Response	2000	668
IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice John S. Cho, Eric M. Pietras, Nairy C. Garcia, Journal of Clinical Investigation Microbial PathogensInnate Immune SystemImmunologyImmunologic MechanismDermatology	2010	633
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, The Lancet Autoimmune DiseaseMedicineClinical TrialsClinical DermatologyModerate-to-severe Plaque Psoriasis	2018	627
Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis Shinji Kagami, Heather L. Rizzo, Jennifer J. Lee, Journal of Investigative Dermatology InflammationCytokineAutoimmune DiseaseMedicineT-regulatory Cell	2009	617
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial Diamant Thaçi, Eric L. Simpson, Lisa A. Beck, The Lancet AllergyAtopic DermatitisAllergy MedicineModerate-to-severe Atopic DermatitisSkin Allergy	2015	560
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky, British Journal of Dermatology	2020	553

Page 1